Dyadic International (DYAI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 20, 2025, with shareholders able to participate and vote online or by phone or mail.
Shareholders will vote on electing one Class III director, ratifying the appointment of Crowe LLP as auditor, approving executive compensation, and determining the frequency of future say-on-pay votes.
The Board recommends voting for all proposals and for an annual frequency on the say-on-pay advisory vote.
The Board will be reduced from six to four members following the retirement of two directors at the meeting.
Proxy materials are distributed primarily via the internet to expedite delivery and reduce costs.
Voting matters and shareholder proposals
Proposals include electing one Class III director, ratifying Crowe LLP as auditor, advisory approval of executive compensation, and advisory vote on frequency of say-on-pay.
Shareholders may submit proposals for the 2026 Annual Meeting by December 30, 2025, following SEC and bylaw requirements.
The Board recommends voting for all proposals and for an annual say-on-pay vote.
Board of directors and corporate governance
The Board will be reduced to four members after the meeting, with a classified structure and staggered three-year terms.
Roles of Chairman and CEO are separated to enhance independent oversight.
All directors attended at least 75% of Board and committee meetings in 2024.
Committees include Audit, Compensation, Nominating, and Science and Technology, each with defined charters and responsibilities.
Independence of directors is assessed per Nasdaq rules; committee members meet independence requirements.
Latest events from Dyadic International
- Commercial product launches and partnerships are driving revenue growth, with more expected by 2027.DYAI
Life Sciences Virtual Investor Forum12 Mar 2026 - Rapid commercialization in non-therapeutic markets targets profitability by 2026.DYAI
Small-Cap Virtual Conference3 Feb 2026 - New partnerships and strong cash position support growth despite lower Q2 revenue.DYAI
Q2 20241 Feb 2026 - Q3 2024 revenue up 5x, net loss narrowed, and cash reserves reached $10M.DYAI
Q3 202414 Jan 2026 - Revenue growth, narrowed losses, and major grants set up multiple product launches in 2025.DYAI
Q4 202419 Dec 2025 - Registering 840,384 shares for resale from convertible notes; no proceeds to the company.DYAI
Registration Filing16 Dec 2025 - Shifted to commercial focus with first bulk sales, global expansion, and strong liquidity.DYAI
Q3 202515 Dec 2025 - Multiple animal-free protein launches and partnerships set the stage for rapid commercial growth.DYAI
IAccess Alpha Virtual MicroCap Conference9 Dec 2025 - Virtual meeting to vote on director, auditor, and executive pay proposals; board recommends approval.DYAI
Proxy Filing2 Dec 2025